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Abstract  
We describe a novel approach to the analysis of toxicogenomics data and elucidation of biological 
networks affected by drug treatments.  In this method approximately 15,000 linear pathway modules 
were generated from manually assembled pathway maps from MetaCore™ (GeneGo, Inc.). 
Microarray expression data from livers of rat exposed to phenobarbital, mestranol and tamoxifen were 
mapped onto these modules. Using different analytical techniques we have identified sets of 
“differential” pathways featuring highly correlated expression among multiple repeats of the same 
treatment while showing strong anti-correlation across different treatments. Network modules 
distinguishing chemical treatments were re-assembled based on these pathways. Unlike traditional 
statistical and clustering procedures in expression profiling, our method takes into account both 
network connectivity and gene expression in the course of the analysis. We demonstrate that it 
enables identification of important cellular mechanisms involved in drug response that would have 
been missed by the analysis based on individual gene expression profiles. 
 
Introduction  
Understanding the effects of treatment by a compound on cellular pathways and networks is 
increasingly important in the evaluation of a drug’s safety [1,2,3,4]. Current analytical procedures in 
toxicogenomics are focused on statistical analysis of expression patterns, aiming at identification of 
small sets of genes (gene signatures) whose expression is significantly altered by treatment, and which 
are the most characteristic for a certain treatment [5,6]. Gene signatures are typically 50-100 genes 
large, and are generated using unsupervised clustering and supervised pattern matching algorithms 
[7,8,9]. These methods are reported to have high predictive power within the experimental set-up 
[10,11,12]. Based on an assumption that similar mechanisms of toxicity will evoke similar patterns of 
gene expression, one can deduce potential toxicity of a compound by comparing the experimentally 
determined signature with a library of standard signatures induced by xenobiotics with known 
toxicity. Some of the reference databases such as CEBS [13] and EDGE [14] are publicly available 
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and others form the basis for commercial toxicity evaluation services by companies such as Iconix 
and GeneLogic. In parallel, data standards and data management systems for toxicogenomics data are 
being developed [15]. However, despite the obvious high utility and ”easy of use” appeal, clinical 
application of toxicity gene signatures is limited, due to poor cross-platform, cross-experiment 
reproducibility [16] and functional inconsistency within signature gene content [17]. Functional 
analysis tools applied in drug response studies so far [2,3,18], have been limited to “enrichment 
analysis” in process and pathways ontologies such as GO [19] and KEGG [20]. Recently, new studies 
incorporate network topology in the analysis of high-throughput datasets [21,22,23, 24, 25, 26,27]. 
For instance, network component analysis [21], a data decomposition method based on the 
connectivity of the regulatory “interactome” was applied for reconstruction of transcription factor co-
operation in cell cycle.  Unlike “static” enrichment analysis in pre-set categories, the network-based 
approach is dynamic, with functional modules uniquely generated for the dataset under investigation. 
They also provide higher resolution at the level of direct binary interactions between proteins, genes 
and compounds.  Previously, we have shown that interconnected protein interaction modules 
(signature networks) can be used as functional descriptors for compound response in vitro [28]. 
Recent case studies have also demonstrated distinct gene expression response networks for aprepitant, 
artemisinin and its analogs, and trovofloxacin [29].   
 
What is most critical here is that the statistical and functional methods outlined above rely on a pre-
selection of differentially expressed genes based on a fold change and/or p-value. This common 
wisdom selection is ubiquitously applied, because statistical thresholds are believed to enhance the 
validity of expression studies and current analytical methods cannot handle thousands of unfiltered 
data points. However, such pre-selection leaves the bulk of the expression profile beyond the scope of 
further functional analysis and thus may substantially change the results.  In current work, we 
reconstruct treatment-specific networks from unfiltered expression data. Unlike the traditional 
workflow of pre-selecting individual genes based on expression followed by the mapping of these 
genes onto predefined static pathways, we have identified the interconnected modules of a global 
protein network with correlated response to drug action. The approach consists of the generation of a 
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large number of relatively small, redundant sub-graphs (pathway modules), mapping of the unfiltered 
treatment-specific expression data on them, followed by a statistical scoring for identification of 
modules that are most perturbed. These modules are then combined into larger network clusters of 
correlated drug response, using a combination of biological and topological criteria. We have applied 
this method to a set of data generated for the response to several long-term drug treatments in livers of 
rat  exposed to Phenobarbital, Mestranol and two doses of Tamoxifen [30,31].  
 
Results and Discussion 
Our objective was to elucidate functional differences between response to phenobarbital, tamoxifen 
and mestranol and to compare these findings with traditional statistical methods and with what is 
known about the effects of these drugs. Phenobarbital, an anticonvulsant used for treating 
neurological disorders such as epilepsy, is also a potent non-genotoxic carcinogen and can promote 
hepatocarcinogenesis in the mice model system [32,33].  To the contrary, Tamoxifen  is a well-
known hormonal antineoplastic agent that inhibits cell growth via an estrogen receptor dependent and 
independent mechanisms. Mestranol is a semi-synthetic alkylated estradiol which directly activates 
estrogen receptor (ESR). ESR-β may suppress breast cancer cell proliferation and tumor formation 
[34] and it has been reported to inhibit cyclin D1 [35] and attenuate the P53 induced apoptosis effect 
[36]. Although the precise roles of ESR-α and ESR-β in liver cancer are unknown, it was shown that 
ESR -β induces liver cancer cell apoptosis in a ligand-dependent manner [37]. Based on this 
information we expected to see similar biological effects between tamoxifen and mestranol, and the 
effect of phenobarbital to be fundamentally different. 
 
Identification of descriptor pathways for drug treatments.  
First, a large set of pathway modules was generated from the collection of “canonical” pathway maps 
manually annotated by GeneGo. These maps are freely available via iPath (www.invitrogen.com). 
The pathway maps display well-understood functional blocks in cell signaling and metabolism and 
therefore are referred to as “canonical” pathways. The pathway modules represent linear sequences of 
protein interactions or metabolic reactions that originate and terminate at biologically meaningful 
 5
start-points (membrane receptors or their ligands) and end-points, (transcriptional factors or their 
immediate targets). All possible pathway modules were generated from each map by an exhaustive 
depth first search algorithm.  The result was a total of 14,582 modules from 145 “canonical” maps 
containing about 1,500 genes (see “Methods” section for details). The pathways had 4.5 steps on 
average and had a high degree of redundancy with every gene participating on average in 10 
pathways. High redundancy was needed for “fine-tuning” the selection of network modules with 
correlated patterns of activity. Indeed, if every gene is included in multiple pathways, most patterns of 
network activity can be closely approximated as a certain combination of these pathways. Pathways 
that were used represent cellular cascades that were described experimentally as working units, and 
therefore are more likely to occur in their entirety, at least in some cell types and processes, than other 
types of network modules. 
 
In the next step, we prioritized the pathways in terms of relevance to treatment-specific gene 
expression datasets. The expression data measured as fold change (treated versus untreated samples) 
was mapped onto the complete set of pathways by matching gene identifiers.  Relative distances 
between samples representing repeats or different treatments were then calculated in the space of gene 
expression of individual pathways using both Pearson correlation and Euclidian distance metrics. 
Euclidian distance is sensitive to changes in amplitude of gene expression, while Pearson distance 
should also identify pathways with small but strongly correlated differences. The overlap between the 
results produced with two metrics should be substantial, however we also expect to find pathways 
uniquely identified by each technique. We have selected pathways identified by Euclidian distance for 
further functional and statistical analysis.  
 
The distances were generated for each qualified pathway among 20 expression datasets: four 
treatments, five repeats for each treatment. We considered a pathway “qualified” if it had at least three 
genes with measured expression in each of the 20 expression datasets. The pathways with fewer than 
three genes with expression were excluded from further analysis. The distance matrices were 
generated for a total of 13,151 qualified pathways. The matrices were initially analyzed using one-
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way ANOVA to identify the pathways for which the distances between samples representing different 
treatments were significantly larger than the distances among the samples representing repeats of the 
same treatment.  In order to perform ANOVA, the distances were arranged in ten groups: four groups 
corresponding to the distances within the four treatments and six groups for the distances across six 
treatment pairs. In order to correct for multiple comparisons we applied the False Discovery Rate 
correction procedure [38] with an experiment significance level of 0.01.  
 
The pathways selected by ANOVA were subjected to the t-test to identify specific treatment pairs for 
which selected pathways are significantly different. Based on the t-test, we selected “descriptor” 
pathways as being the most differentiating between pairs of treatments. The largest number of 
descriptor pathways were identified for the pair phenobarbital - tamoxifen (Table 1). Remarkably, 
there were no pathways that differentiated between tamoxifen and mestranol responses and between 
the two concentrations of tamoxifen. These results are consistent with biological differences and 
similarities of these drugs’ effects mentioned above. Indeed, phenobarbital is known to induce cell 
proliferation and tumor growth while tamoxifen is an estrogen antagonist with clear anti-growth 
effect. On the other hand, mestranol is a synthetic analog of estradiol and similar to tamoxifen in its 
ability to interact with estrogen receptor.  Application of Pearson distance yielded more differentiating 
pathways in each comparison than the Euclidian distance. This indicates that differences between 
treatments may manifest themselves not only in amplitude of expression change along a pathway but 
also as small coordinated changes in expression for a whole pathway. Such pathways are missed by 
the analysis based on Euclidian distances but are identified in Pearson correlation distance matrix.  
 
In the next step, we exported all genes from the descriptor pathways and organized them as non-
redundant gene lists characteristic for each pair of treatments. The number of genes differentiating 
between treatments are shown in Table 1.  The relatively small number of genes compared to the 
number of pathways is an indication that the descriptor pathways share a large number of common 
genes. We compared the intersection between the gene lists differentiating between treatments (Fig. 
1).  51% of the genes from phenobarbital-mestranol list were common with the phenobarbital-
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tamoxifen (low dose) pair and 79% genes with the phenobarbital-tamoxifen (high dose) list (Fig. 1).  
The descriptor genes for phenobarbital and the two concentrations of tamoxifen pairs highly 
overlapped (close to 90%), the descriptor genes for phenobarbital tamoxifen (low dose) representing a 
subset of the descriptor group for the Phenobarbital-Tamoxifen (high dose) pair. Our observations are 
consistent with the degree of similarity between treatments and make biological sense. Indeed, the 
most similar treatments, those for the two doses of the same drug (tamoxifen) show no significant 
differences in affected pathways.  Furthermore, there were no descriptor pathways for mestranol-
tamoxifen pair. Indeed, mestranol and tamoxifen, have similar biological targets (both are ligands for 
the estrogen receptor), while phenobarbital is distinct from this pair, both structurally and by mode of 
action.  
 
Differential response networks.  
The characteristic gene lists for treatment pairs were used as input files for the generation of 
biological networks in MetaCore [28]. Two gene lists were generated for each treatment pair via 
ANOVA test of the sample-sample matrix. The networks were built by direct interactions (DI) 
algorithm which allows visualization of only the edges which correspond to direct physical 
interactions between the input nodes; in this case the protein products of the genes from the 
characteristic lists (Fig. 2). The interconnected parts of the networks contained 99 and 37 nodes for 
Phenobarbital-tamoxifen and for Phenobarbital-mestranol pairs, respectively. To test the significance 
of the results we randomly changed the labels of the genes across the entire expression data set and 
repeated the analysis 100 times. As we expected the random mixing of labels broke the association 
between expression profile and network topology, leading to a smaller number of differentiating 
pathways (genes).  We did not find any gene differentiating between most of the treatment pairs and 
identified a much lower number of genes differentiating between Phenobarbital and the two different 
concentrations of tamoxifen (both corresponding to p=0.05) We also investigated the topological 
properties of the networks. Some of the properties of differential networks showed significant 
differences in comparison to networks generated from a set of randomly picked pathways (Table 2).  
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The resulting networks were overlaid with expression data presented as a ratio between treated and 
untreated liver expression (Fig. 2). Expression of the majority of the genes on these networks are anti-
correlated between treatments. The fold change difference for the genes on the networks varied 
between 1% and 65% and standard t-test p-values of individual data points between 10-e4 and 0.97. 
Therefore, a large fraction of these genes (55% for p<0.1 threshold) would have been excluded from 
the analysis by any conventional microarray analysis procedure based on statistical significance of 
individual genes. We have also identified the network modules specific for certain functional 
processes (Figure 2c), by selecting subsets annotated to particular biological processes as defined by 
Gene Ontology [19].  
 
The networks can also be characterized and compared based on their global topology features such as 
the number of nodes, presence of highly connected nodes (hubs), in- and out-going edges, 
transcription factors, and receptors involved in the networks etc. The top 10 hubs defined by the 
number of connections and the top 10 transcription factors are shown in Table 2. 
 
We also calculated average degree, average clustering coefficient, average shortest path and centrality 
of the nodes for three types of networks: the global interconnected cluster based on all interactions in 
the MetaCore™ database, the network of protein content from MetaCore™ canonical maps connected 
through direct interactions; and differential response networks. We calculated the network properties 
in the global protein interaction network and averaged the quantities over the proteins identified as 
differentiating between the treatments. The network for proteins gleaned from our maps feature higher 
than average degree (in- and out degree), clustering coefficient, centrality and shorter than average 
shortest path than the global network. This was expected, as maps are generated from the pathways 
experimentally shown to be the main signaling conduits and metabolic fluxes in human cells.  
However, the substantial differences in some of the topological properties between drug response 
networks and networks built from proteins on our maps were surprising (Table 2). In order to assign 
statistical significance to these differences we calculated p-values of networks created from a set of 
randomly chosen pathways (same as the real number of differentiating pathways). The drug response 
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network for Phenobarbital and tamoxifen (low dose) featured a disproportionately high fraction of 
“hubs”, manifested in significantly higher average node degree for both incoming and outgoing 
interactions. Similar tendencies were reported for protein interaction networks in yeast for essential 
proteins and toxicity modulation proteins [39,40]. Interestingly, the descriptor network for 
phenobarbital vs. tamoxifen (high dose) pair features a slightly lower clustering coefficient, probably 
reflecting a different drug response mechanism. The shorter than average shortest path may be 
associated with a network optimized for a quick response time.   
 
Functional analysis of signature networks.  
Using MetaCore™ tools, we performed functional enrichment analysis for the gene content of 
differential response networks’ using canonical pathway maps and Gene Ontology (GO) processes. 
The distribution of the top 10 canonical maps and GO processes for two signature networks (for 
mestranol vs. phenobarbital and tamoxifen vs. phenobarbital) is shown in Table 3.  The statistical 
significance of functional maps was evaluated by Monte-Carlo procedure as described in “Methods” 
section. In this procedure we have simulated random selection of sets of pathway modules with 
subsequent mapping onto maps. We choose this procedure over hypergeometric distribution to 
account for the fact that genes in differential response networks are always selected as part of a 
pathway module, rather than individually. The networks for phenobarbital-tamoxifen and 
phenobarbitral-mestranol pairs displayed quite different enrichment profiles despite the fact that they 
share one of the counterpart treatments (phenobarbital). We suggest that the two networks reflect 
different functional aspects of drug action mechanism. Most of the top scoring maps distinguishing 
phenobarbital and tamoxifen are related to cell cycle regulation (Table 3). Remarkably, all of the top 
four GO categories for this treatment pair are also related to cell cycle or its elements. This indicates 
that our method is robust in identifying cell proliferation effect of phenobarbital when compared to 
tamoxifen. On the other hand, differences between phenobarbital and mestranol are most prominent in 
how these drugs affect signal transduction such as MAP-kinase pathway, growth-factor signaling, etc. 
We believe that this is mostly due to the prominent hormonal role of mestranol. This is further 
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confirmed by top GO processes related to phenobarbital-mestranol network, which include signal 
transduction, phosphorylation and cell communication.  
 
Closer examination of top scoring maps reveals some interesting mechanistic observations. For 
instance, they show opposite effects of phenobarbital and tamoxifen on major elements of the cell 
cycle. These effects are very modest in magnitude, rarely exceeding 40% change in gene expression 
but very consistent for most of the pathway elements. Figure 3a shows an overview map of mitosis 
initiation with gene expression data for all three drugs mapped on it. The map is one of the top-scored 
maps for phenobarbital-tamoxifen comparison and has four transcription factors serving as pathway 
inputs: c-Myc, AP-2A, USF1 and FOXM1. All four are up-regulated by phenobarbital treatment and 
down-regulated by tamoxifen and mestranol treatments. The major target of these transcription factors 
is cyclin B1, which in turn activates CDK1 – a key regulator of entry into mitosis.  Earlier, it was 
shown that treatment of c-Myc transgenic mice with Phenobarbital indeed results in tremendous 
acceleration of neoplastic development in the liver compared with non-treatment of c-Myc mice or 
treatment of wild-type mice with Phenobarbital [33]. The role of FOXM1 in liver carcinomas is also 
documented [41],.   
 
Interestingly, this map shows fairly similar expression profiles for tamoxifen and mestranol, yet only 
two genes from phenobarbital-mestranol differential response network are present on it. This serves as 
an early indication that our technique is capable to detect pathways with small but consistent 
quantitative variations in gene expression which may result in phenotype divergence. Indeed despite 
that all gene expression variations appear equally small strong association of phenobarbital-tamoxifen 
network with cell cycle points to major differences these drugs might have had on liver cell 
proliferation if administered for longer time or at higher doses.  Majority of descriptive genes 
identified by our method would have been rejected by any “rule of thumb” constraints used in 
microarray analysis. For example, a mild constraint of fold change > 1.4 and p < 0.1 leaves no 
“differentially expressed” genes on the mitosis map   Moreover, if statistical constraints are imposed 
on the gene expression data prior to mapping, all maps presented above are scored low, and therefore 
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are not even considered as a relevant functional descriptor between the datasets. We applied 
conventional t-test (Phenobarbital vs. Tamoxifen (low dose)) to identify the genes differentiating 
between treatment pairs. We note that after we applied the False Discovery Rate approach at 
significance level 0.01 we found only 9 genes differentiating between the two treatment pairs. Further, 
a less stringent cutoff of p<0.01 and no multiple testing correction yielded 330 differentiating genes.  
The functional analysis of these genes showed that there were only two significantly enriched 
pathway maps with no clear connection with the treatment pairs (Ral1A regulation pathways and 
A2BR signaling via G-beta/gamma dimmer). The top maps identified by our method were not 
significantly enriched in the differentiating genes based on the t-test, the p-values being larger than 
any reasonable threshold (p>0.1 for most top maps). For example, the “start of mitosis” map has only 
a single protein, Cyclin B1 (Fig 3a, circled in green) which is differentiating between phenobarbital 
and tamoxifen based on the t-test. 
  
We compared our method with the traditional hierarchical clustering approach that relies on the fold 
changes of individual genes. We calculated the Pearson distance between the log ratios of gene 
expression profiles of individual genes and performed standard hierarchical clustering [42] on all 
genes with expression data for each of 20 datasets which are present on the generated pathways.  The 
genes not present on pathways were excluded. Clustering failed to clearly identify gene sets with any 
difference on a pathway level, which is well consistent with literature. To illustrate this point further, 
we marked genes identified by our pathway-based method with bars of different color based on 
treatment comparisons (Fig. 3b). None of these bars seem to form any cohesive groups on the 
clustering map, suggesting that clustering cannot identify descriptor genes which form cohesive 
differential-response networks.  
 
Methods 
Gene expression datasets. 
 Gene expression data were produced as part of the program to study effects of long-term drug 
exposure at the National Center for Toxicological Research [33]. Female rats were administered the 
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AIN-76A basal diet or a diet containing the drugs mixed into the basal diet at 500 mg Phenobarbital 
per kg diet, 2 mg mestranol per kg diet, and tamoxifen at either 250 mg per kg diet (designated as 
low) or 500 mg per kg diet (designated as high).  Overall, five treatment groups were used in the 
experimental design: control, phenobarbital, mestranol, and 2 doses of tamoxifen.  RNA from rat 
livers was isolated and used for the microarray experiment.   All samples were co-hybridized with 
Stratagene universal rat reference RNA. The design is a 2-color common reference design experiment 
with the samples labeled with Cy5 and the reference always labeled with Cy3.  The 10,000 rat 
oligonucleotide probes were purchased from MWG and printed onto poly-L-lysine slides at NCTR 
Center for Functional Genomics. For each treatment group data for five biological repeats were 
assayed. For further analysis, we have computed log-ratio for treated vs. untreated animals according 
to the following formula:  
 
log2 (fold change) = log2(T/C) = log2(T/R) - log2(C/R'), where  
 
T = signal from treated sample 
C = signal from control (untreated sample) 
R = signal from reference sample for treatment 
R' = signal from reference sample for control 
 
Generation of the sample-sample distance matrix.  
After mapping gene expression data onto pre-computed pathway modules the matrix of sample-
sample distances was calculated. Distances were calculated in the gene expression space of every 
individual pathway module.  
We used both Euclidian distance and Pearson correlation (in Supplementary Materials) for calculating 
two distance matrices. The Pearson distance between samples x and y for a pathway of n genes is 
calculated as ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −−= ∑
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i
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n
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11 , where xi and yi are the gene expression log ratios  
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for genes i  in sample x and y, and x , y , xσ , yσ  are the mean values and respective standard 
deviations. Similarly, the Euclidian distance is calculated as ( )∑
=
−=
n
i
iiyx yxd
1
2
, .  After 
calculating all distances, the procedure results in two matrices of sample-sample distances. Each row 
of these matrices corresponds to a pathway module and each column represents a sample pair. Thus 
for 20 samples (5 repeats for each treatment) the size of each matrix is 13,151X190.   
  
Identifying condition-specific pathways modules based on ANOVA and t-test. 
Calculated sample-sample distances were separated into 10 groups. Four groups correspond to 
individual drug treatments and contain distances between repeats of the same treatment. Six groups 
contain distances from individual repeats of one treatment to individual repeats of another for all six 
possible treatment pairs. Using these groups we performed one-way ANOVA analysis to reveal 
pathways for which there are groups with significantly different distance distributions. Alternatively, 
as the normality requirement for ANOVA may not necessarily hold for sample-sample distance 
distribution, we applied the Kruskal-Wallis method which gave identical results. After ANOVA 
pathways were rank ordered according to calculated p-values and the False discovery rate correction 
was applied, only the pathways for which pk< α*k/m were selected for further analysis. Here m = 
13,151 number of pathways tested, k is the rank of individual pathway, and α = 0.01 is experiment 
significance level.  For the pathways selected by ANOVA and subsequent FDR correction, the pair-
wise t-test was performed to determine which specific groups of distances are significantly different. 
For the t-test, a 0.01 significance-level was used and the Bonferroni correction was applied. As the 
number of comparisons for each pathway is twelve (two comparisons for each of the six treatment 
pairs) the corrected significance level we used is 8.3e-4. The selected pathways were grouped into 
“clusters” based on the t-test results and we selected the ones which clearly distinguish between two 
treatments. Specifically, we selected those for which there existed particular pair of treatments so that 
distances among repeat samples for the same treatment are significantly smaller than the inter-
treatment distances. For instance, the pathways that distinguish mestranol from tamoxifen treatment 
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had to satisfy the condition that both distances between mestranol repeats and distances between 
phenobarbital repeats are statistically smaller than the mestranol-phenobarbital distances. 
 
Evaluating significance of functional enrichment.  
We evaluated statistical significance of the enrichment of functional maps by using a randomization 
procedure.  To account for the fact that genes in our mappings are derived from “differentiating” 
pathway modules, our procedure started with randomly picking pathways modules rather than 
individual genes. Pathways were selected until we reached the same size of gene content as the size of 
our differential response networks.  In order to achieve exactly the same number of genes, once the 
gene content of randomly picked pathway modules became larger than our differentiating gene set we 
simply corrected by retaining an appropriate subset of interconnected genes from one of the randomly 
picked pathway modules. We repeated this procedure 1,000,000 times, each time calculating the 
overlaps of a resulting set of genes with all functional maps.  Next we calculated the overlaps of gene 
sets derived from differential response networks with every map and estimated p-values as relative 
frequency of instances where the random sets had higher overlap with a map than the differentiating 
set of genes.  
We applied FDR at 0.01 significance level and identified 8 map significantly enriched for 
Phenobarbital and Mestranol treatments and 16 maps significantly enriched for Phenobarbital and 
Tamoxifen treatments. 
 
Topological measures    
Degree of nodes. The number of links connected to a node gives the node’s degree. Since many real 
networks are directed, nodes are characterized by in and out-degree, giving the number of outgoing 
and incoming interactions. While calculating average degree of nodes in a network, we average over 
the degree of the nodes which are part of that network, but considering all interactions they have in 
the global network. Similarly, while calculating clustering coefficient we consider all interactions of a 
node in the global network.  
 15
Average shortest path. The shortest distance between two nodes is the number of links along the 
shortest path. The average shortest path is the average over the shortest paths for all node pairs in the 
network.  When we calculate the shortest paths for a subset of nodes in the network we consider also 
paths crossing through nodes which are not part of the subset.     
Average clustering coefficient.  The clustering coefficient is a measure that captures to what degree 
node’s neighbors are connected. It is defined as: 
)1(
2
−= ii
i
i kk
n
C , where ni is the number of links 
among the ki neighbors of node i. As ki(ki-1)/2 is the maximum number of such links, the clustering 
coefficient is a number between 0 and 1. The average clustering coefficient is obtained by averaging 
over the clustering coefficient of individual nodes.  A network with high clustering coefficient is 
characterized by highly connected sub-graphs. 
Centrality of nodes. Centrality of a node is the number of shortest paths going through that node when 
we consider the shortest path between all node pairs.  When there is more than one shortest path 
between two nodes the centrality is divided by the number of shortest paths between them. The 
centrality of a node (k) can be calculated as: 
∑
≠
=
ji ij
ij
k
k
C σ
σ )(
, 
 
where σij is the number of shortest paths between i and j, σij(k) is the number of shortest paths 
between i and j which passes through k.  
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Tables  
Table 1. The number of pathways and genes differentiating between the treatment pairs.   The 
microarray data were produced as follows: female rats were administered the AIN-76A basal diet or 
that diet containing the drugs admixed into the basal diet at 500 mg Phenobarbital per kg diet, 2 mg 
mestranol per kg diet, and tamoxifen at either 250 mg per kg diet (designated as low) or 500 mg per 
kg diet (designated as high).   
 
 
 
Treatments Number of 
differentiating 
pathways  
Number of 
differentiating 
genes 
Phenobarbital vs. 
mestranol 
12 58 
Phenobarbital vs. 
tamoxifen (low) 
123 146 
Phenobarbital vs. 
tamoxifen (high) 
261 334 
Mestranol vs. 
Tamoxifen (low) 
0 0 
Mestranol vs. 
Tamoxifen (high) 
0 0 
Tamoxifen (low) vs. 
Tamoxifen (high) 
0 0 
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Table 2. Network characteristics. 
A) Topological characteristics of differential drug response networks compared to global 
network. Values with statistically significant differences are highlighted in bold and values 
are calculated in the global protein interaction network and averaged over the set of 
differential genes. Only p-values below 0.1 are indicated in the table. B) The top 10 hubs and 
transcriptional factors characterized by highest connectivity calculated in the “differential” 
response networks (Fig. 1)     
(A) 
Topological 
properties 
Global 
network 
Proteins from 
maps 
Phenobarbital 
–Mestranol 
Phenobarbital-
Tamoxifen(low) 
Phenobarbital- 
Tamoxifen 
(high) 
  Degree 10.7 27.68 49.57  45.23 (p=0.004) 38.14 (p=0.08) 
In-degree 5.27 13.09 27.08  23.36 (p=0.004) 19.26 
Out-degree 5.37 15.52 22.49  21.87  (p=0.02) 18.88 (p=0.05) 
Clustering 
coefficient 
0.14 0.14 0.15 0.14 0.12 
Shortest path  4.42 3.27 2.33 (p<0.001) 2.74 (p<0.001) 3.04 (p=0.06) 
Centrality 
(104) 
9.9 23.5 39.5 
 
35.5 
 
30.92 (p=0.1) 
 
 
 
(B) 
Phenobarbital/Tamoxifen network 
Hubs  Connectivity Transcription factors Connectivity
p53 34 P53 34 
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CDK1(p34) 30 STAT3 18 
c-Src 27 c-Cbl 17 
Shc 24 c-Jun 17 
SHP-2 23 CREB1 17 
GRB2) 22 E2F1 13 
JAK2 22 AP-2A 9 
PI3K  19 HIF1A 9 
Phenobarbital/Mestranol network 
Hubs  Connectivity TFs Connectivity
RelA (p65) 20 RelA (p65) 20 
NFKBIA 19 c-Fos 14 
c-Src 18 c-Jun 13 
c-Fos 14 NF-KB1 13 
EGFR 14 NF-KB1 (p105) 13 
c-Jun 13 c-Rel 10 
IRS-1 13 NF-kB p50/p65 10 
NF-kB1 13 NF-kB2 (p100) 10 
Erk (MAPK1/3) 12 RelB 10 
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Table 3. Functional characteristics of phenobarbital/mestranol and phenobarbital/tamoxifen 
differential response networks  
 
Pathway maps p-value Gene Ontology “Biological process” p-value 
Phenobarbital – tamoxifen (low) comparison 
Peroxisomal branched chain fatty 
acid oxidation 
4.40E-05 cell cycle 1.67E-08 
Role APC in cell cycle regulation 8.10E-05 regulation of cell cycle 2.20E-08 
H-RAS regulation pathway 0.000201 regulation of progression through cell 
cycle 
5.91E-08 
The metaphase checkpoint 0.000685 transmembrane receptor protein 
tyrosine kinase signaling pathway 
3.93E-07 
Start of the mitosis 0.000742 mitotic cell cycle 7.21E-07 
Propionate metabolism p.2 0.001004 Mitosis 1.22E-06 
Spindle assembly and chromosome 
separation 
0.001324 enzyme linked receptor protein 
signaling pathway 
2.30E-06 
FGF-family signaling 0.001448 organ morphogenesis 3.39E-06 
Saturated fatty acid biosynthesis 0.001904 Biopolymer modification 6.19E-06 
Mitochondrial unsaturated fatty acid 
beta-oxidation 
0.002405 Morphogenesis 6.41E-06 
 
Phenobarbital – mestranol comparison 
GDNF family signaling <1.00E-06 signal transduction 2.43E-11 
EGF signaling pathway 3.00E-05 cell communication 1.35E-10 
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MAPK cascade. Part II, Map 1 - 
MAP4K2-4 - ERK5 & JNK pathway 
3.40E-05 phosphorylation 2.19E-09 
H-RAS regulation pathway 0.00013 intracellular signaling cascade 7.79E-09 
PDGF signaling via STATs and NF-
kB 
0.000203 phosphate metabolism 1.47E-08 
Pleckstrin homology proteins 
interactions. Part III 
0.000303 phosphorus metabolism 1.47E-08 
Angiopoietin - Tie2 signaling 0.000323 protein kinase cascade 2.45E-08 
Role of PDGFs in cell migration 0.000365 protein amino acid phosphorylation 2.53E-08 
A2A receptor signaling 0.000765 biopolymer modification 8.78E-07 
MAPK cascade. Part I.  Map 1. 
ERK-related pathways 
0.001292 anatomical structure development 2.31E-06 
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Figures 
 
 
Figure 1. Characterizing the overlap between groups of genes identified as differentiating between 
treatment conditions.  Approximately 51% of the genes from phenobarbital-mestranol list were 
common with the phenobarbital-tamoxifen (low dose) pair and 79% genes with the phenobarbital-
tamoxifen (high dose) list.  The descriptor genes for phenobarbital and the two concentrations of 
tamoxifen pairs highly overlap (close to 90%). 
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Figure 2. Differential drug-response networks are based on pathways that differentially respond to 
treatments. (a) Direct interaction network assembled from a group of genes from pathways 
differentiating mestranol and phenobarbital treatments. Relative changes in expression between 
treated and untreated rats are mapped (log-ratios, averaged over 5 repeats).  Atop each network, we 
noted the treatment to which gene expression profile corresponds. (b) The network assembled from 
the genes extracted from pathways that distinguish phenobarbital from tamoxifen. Note that both 
comparisons contain significant numbers of genes that are anti-correlated between treatments. (c). A 
sub-graph network connecting only the genes annotated to “cell cycle” in Gene Ontology   
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Figure 3. Differential drug response data on maps and bi-clustering of genes. (a) “Start of mitosis” 
map is one of top scored map for the enrichment in the set of genes from the network differentiating 
between tamoxifen and phenobarbital treatments. Thermometer-like icons correspond to over- (red) 
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and under- (blue) expression and numbered to indicate treatment to which they correspond. 
Expression data for phenobarbital (#1), tamoxifen  (lower concentration, #2) and mestranol (#3) are 
mapped without pre-filtering. Note that most genes on this map are consistently under expressed for 
tamoxifen and over-expressed for phenobarbital treatments, resulting in a map clearly differentiating 
between the two responses. The green circle shows the only gene that was identified as differentiating 
between the two treatments by a conventional t-test. Boxes indicate proteins that are members of 
differential response networks for phenobarbital-tamoxifen (blue) and phenobarbital-mestranol (red). 
Since differential response networks are built from whole pathway modules, some of their member 
proteins may have no expression data associated with them. 
(b) Bi-clustering of genes and treatments based on expression. Only the genes that could be mapped 
onto our set of pathway modules are used in clustering.  Colored bars identify genes selected by our 
pathway-based method as differentiating between treatments: red - phenobarbital vs. mestranol, green 
- phenobarbital vs. tamoxifen (low), blue - phenobarbital vs. tamoxifen (high). 
 
 
 
